Novo Secures Cardiovascular Expansion for Semaglutide Pill
Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events in at-risk patients with type 2 diabetes.
Mounjaro: What is the ‘golden dose’ and what are the risks?
Post Content
Head of addiction medicine society warns of treatment cuts and rising threat of gambling
BOSTON — The president of a leading addiction medicine group issued stark warnings on hardline Trump administration policies on substance use, low rates of addiction treatment uptake, and a rise in problem gambling. But Stephen Taylor, the president of the American Society of Addiction Medicine, tempered his remarks with optimism. In particular, he expressed hope […]
Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) – Seeking Alpha
Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE) Seeking Alpha FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk The Wall Street Journal First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved New Atlas FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type […]
How big is the GLP-1 wave going to get, really?
GLP-1 drugs like Ozempic and Wegovy are transforming public health and consumer habits. Here we explore their explosive growth, future potential, and impact on the food industry.
BF Biosciences brings GLP-1 manufacturing to Pakistan
BF Biosciences Ltd has begun local manufacturing of tirzepatide, bringing one of the world’s most sought-after metabolic drugs into production on Pakistani soil. In a material disclosure to the Pakistan Stock Exchange, the company said it has launched Zeptide (tirzepatide) in an easy-to-use pre-filled syringe, produced at its new European-specification pre-filled syringes facility. The company […]
FDA Approves Rybelsus (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes Who Are at High Risk
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 17, 2025 /PRNewswire/ — Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major…
First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk’s once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke. Continue Reading Category: Diabetes, Illnesses and conditions, Body and Mind Tags: Novo Nordisk, Heart Disease, Cardiovascular […]
Lilly’s oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Reconfirming Its Potential as a Foundational Treatment in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron…
Doctors Just Found Something Fascinating About What Happens When You Drink on Ozempic
GLP-1 drugs like semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, were originally intended to treat diabetes — and didn’t become blockbuster prescriptions until doctors realized that they were also potent weight loss aids that seem to re-wire patients’ relationship to food and satiety. Since then, it’s slowly been emerging that they have […]